EA201790143A1 - Кристаллический (2s)-3-[(3s,4s)-3-[(1r)-1-гидроксиэтил]-4-(4-метокси-3-{[1-(5-метилпиридин-2-ил)азетидин-3-ил]окси}фенил)-3-метилпирролидин-1-ил]-3-оксопропан-1,2-диол - Google Patents

Кристаллический (2s)-3-[(3s,4s)-3-[(1r)-1-гидроксиэтил]-4-(4-метокси-3-{[1-(5-метилпиридин-2-ил)азетидин-3-ил]окси}фенил)-3-метилпирролидин-1-ил]-3-оксопропан-1,2-диол

Info

Publication number
EA201790143A1
EA201790143A1 EA201790143A EA201790143A EA201790143A1 EA 201790143 A1 EA201790143 A1 EA 201790143A1 EA 201790143 A EA201790143 A EA 201790143A EA 201790143 A EA201790143 A EA 201790143A EA 201790143 A1 EA201790143 A1 EA 201790143A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methylpyridin
oxy
diol
hydroxyethyl
methoxy
Prior art date
Application number
EA201790143A
Other languages
English (en)
Other versions
EA031089B1 (ru
Inventor
Пин Хуан
Сет Дитрих Райб
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201790143A1 publication Critical patent/EA201790143A1/ru
Publication of EA031089B1 publication Critical patent/EA031089B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описан кристаллический (2S)-3-[(3S,4S)-3-[(1R)-1-гидроксиэтил]-4-(4-метокси-3-{[1-(5-метилпиридин-2-ил)азетидин-3-ил]окси}фенил)-3-метилпирролидин-1-ил]-3-оксопропан-1,2-диол и его фармацевтические композиции. В настоящем изобретении также описаны способы применения данного соединения для лечения гиперактивности мочевого пузыря.
EA201790143A 2014-09-04 2015-08-28 Кристаллический (2s)-3-[(3s,4s)-3-[(1r)-1-гидроксиэтил]-4-(4-метокси-3-{[1-(5-метилпиридин-2-ил)азетидин-3-ил]окси}фенил)-3-метилпирролидин-1-ил]-3-оксопропан-1,2-диол EA031089B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/085925 WO2016033776A1 (en) 2014-09-04 2014-09-04 Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
PCT/US2015/047415 WO2016036596A1 (en) 2014-09-04 2015-08-28 Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol

Publications (2)

Publication Number Publication Date
EA201790143A1 true EA201790143A1 (ru) 2017-06-30
EA031089B1 EA031089B1 (ru) 2018-11-30

Family

ID=54073019

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790143A EA031089B1 (ru) 2014-09-04 2015-08-28 Кристаллический (2s)-3-[(3s,4s)-3-[(1r)-1-гидроксиэтил]-4-(4-метокси-3-{[1-(5-метилпиридин-2-ил)азетидин-3-ил]окси}фенил)-3-метилпирролидин-1-ил]-3-оксопропан-1,2-диол

Country Status (26)

Country Link
US (1) US10065942B2 (ru)
EP (1) EP3189044B1 (ru)
JP (1) JP6364545B2 (ru)
KR (1) KR20170038884A (ru)
CN (1) CN107001327B (ru)
AP (1) AP2017009774A0 (ru)
AU (1) AU2015312229B2 (ru)
BR (1) BR112017003010A2 (ru)
CA (1) CA2956517A1 (ru)
CL (1) CL2017000467A1 (ru)
CO (1) CO2017001097A2 (ru)
CR (1) CR20170051A (ru)
DO (1) DOP2017000037A (ru)
EA (1) EA031089B1 (ru)
EC (1) ECSP17013015A (ru)
ES (1) ES2688167T3 (ru)
IL (1) IL250356A0 (ru)
MA (1) MA40606A (ru)
MX (1) MX2017002688A (ru)
NZ (1) NZ728359A (ru)
PE (1) PE20170442A1 (ru)
PH (1) PH12017500400A1 (ru)
SG (1) SG11201701608RA (ru)
TN (1) TN2017000045A1 (ru)
TW (1) TWI570119B (ru)
WO (2) WO2016033776A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101696A1 (es) * 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
WO2021036953A1 (zh) * 2019-08-23 2021-03-04 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7585882B2 (en) * 2004-10-20 2009-09-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
KR20080056250A (ko) 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JO3264B1 (ar) 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Also Published As

Publication number Publication date
TWI570119B (zh) 2017-02-11
WO2016033776A1 (en) 2016-03-10
BR112017003010A2 (pt) 2017-12-12
US10065942B2 (en) 2018-09-04
CN107001327B (zh) 2022-09-02
EP3189044B1 (en) 2018-08-01
TW201619149A (zh) 2016-06-01
US20170233373A1 (en) 2017-08-17
KR20170038884A (ko) 2017-04-07
IL250356A0 (en) 2017-03-30
EA031089B1 (ru) 2018-11-30
DOP2017000037A (es) 2017-02-28
AU2015312229A1 (en) 2017-02-02
ES2688167T3 (es) 2018-10-31
SG11201701608RA (en) 2017-03-30
CA2956517A1 (en) 2016-03-10
AU2015312229B2 (en) 2017-11-16
WO2016036596A1 (en) 2016-03-10
ECSP17013015A (es) 2018-03-31
PE20170442A1 (es) 2017-04-26
CO2017001097A2 (es) 2017-04-28
CR20170051A (es) 2017-04-26
NZ728359A (en) 2018-08-31
TN2017000045A1 (en) 2018-07-04
MX2017002688A (es) 2017-05-30
EP3189044A1 (en) 2017-07-12
JP2017525747A (ja) 2017-09-07
MA40606A (fr) 2016-03-10
CL2017000467A1 (es) 2017-10-20
AP2017009774A0 (en) 2017-02-28
PH12017500400A1 (en) 2017-07-17
JP6364545B2 (ja) 2018-07-25
CN107001327A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA201790630A1 (ru) Способы получения рибозидов
CU24406B1 (es) 1-{[(2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il]metoxi}-7 -metoxiisoquinolin-6-carboxamida
EA201691302A1 (ru) Новые гетероциклические соединения
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA202092620A1 (ru) Соли и твердые формы монобактамного антибиотика
EA201691141A1 (ru) Соединения против ccr6
EA201790570A1 (ru) Модуляторы р2х7
EA201792287A1 (ru) Способы лечения рака
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
PE20170328A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201790445A1 (ru) Производные индолинона и их применение
EA201691544A1 (ru) Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения
EA201591498A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201790613A1 (ru) Триазольные соединения в качестве блокаторов кальциевых каналов т-типа
EA201890177A1 (ru) Мультиспецифические связывающие белки
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU